New combo therapy aims to fight Hard-to-Treat cancers
NCT ID NCT07390383
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called LBL-024 combined with other cancer drugs (capecitabine, tislelizumab, and oxaliplatin) in 110 adults with advanced solid tumors. The goal is to see if the combination shrinks tumors and is safe. Participants must be in good overall health and have a life expectancy of at least 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LBL-024 (an experimental drug) combined with capecitabine, tislelizumab, and oxaliplatin
What this could lead to
If successful, this could point toward a new combination treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is an early Phase 2 trial with only 110 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Beijing GoBroad Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100070, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial Cancer Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Qingdao University
NOT_YET_RECRUITINGQingdao, Shandong, 266000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Fourth Hospital of Hebei Medical University
NOT_YET_RECRUITINGShijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300202, China
Contact Phone: •••-•••-•••• Email: •••••@•••••